Table 3.
Correlation between miR-675-3p expression and clinicopathological features
| Variables | Total (N = 230) | miR-675-3p expression | p value | |
|---|---|---|---|---|
| High (N = 115) | Low (N = 115) | |||
| Age (year) | ||||
| < 65 | 120 (52.2%) | 61 (53.0%) | 59 (51.3%) | 0.792 |
| ≥ 65 | 110 (47.8%) | 54 (47.0%) | 56 (48.7%) | |
| Gender | ||||
| Male | 144 (62.6%) | 68 (59.1%) | 76 (66.1%) | 0.276 |
| Female | 86 (37.4%) | 47 (40.9%) | 39 (33.9%) | |
| Family history of cancer | ||||
| No | 133 (57.8%) | 66 (57.4%) | 67 (58.3%) | 0.713 |
| Yes | 67 (29.1%) | 32 (27.8%) | 35 (30.4%) | |
| Unknown | 30 (13.0%) | 17 (14.8%) | 13 (11.3%) | |
| TNM stage | ||||
| I | 57 (24.8%) | 31 (27.0%) | 26 (22.6%) | 0.531 |
| II | 78 (33.9%) | 35 (30.4%) | 43 (37.4%) | |
| III | 89 (38.7%) | 47 (40.9%) | 42 (36.5%) | |
| IV | 6 (2.6%) | 2 (1.7%) | 4 (3.5%) | |
| Histologic grade | ||||
| G1–G2 | 155 (67.4%) | 70 (60.9%) | 85 (73.9%) | 0.035* |
| G3–G4 | 75 (32.6%) | 45 (39.1%) | 30 (26.1%) | |
| Pathologic_M | ||||
| M0 | 224 (97.4%) | 113 (98.3%) | 111 (96.5%) | 0.408 |
| M1 | 6 (2.6%) | 2 (1.7%) | 4 (3.5%) | |
| Clark's level | ||||
| I–III | 47 (20.4%) | 17 (14.8%) | 30 (26.1%) | 0.034* |
| IV–V | 183 (79.6%) | 98 (85.2%) | 85 (73.9%) | |
| Pathologic_N | ||||
| N0–N1 | 135 (75.2%) | 69 (60.0%) | 66 (57.4%) | 0.688 |
| N2–N4 | 95 (24.8%) | 46 (40.0%) | 49 (42.6%) | |
| Pathologic_T | ||||
| T1–T2 | 82 (35.7%) | 45 (39.1%) | 37 (32.2%) | 0.271 |
| T3–T4 | 148 (64.3%) | 70 (60.9%) | 78 (67.8%) | |
*indicates statistically significant. The high expression of miR-675-3p was correlated with tumor histologic grade and Clark’s level